Sertoli-Leydig Cell Tumor of the Ovary

Sertoli-Leydig Cell Tumor of the Ovary, explained simply

Everything a patient or caregiver wants to understand: what sertoli-leydig cell tumor of the ovary is, how doctors describe its stage, the standard treatment plan, how radiation works, and the research shaping care today.

On this page

Watch: the CureRays® explainer series

Watch Dr. Hess explain radiation therapyPlain-language videos on how radiation works, what treatment feels like, and what to expect — on the CureRays® YouTube channel.

Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.

What is sertoli-leydig cell tumor of the ovary?

Sertoli-Leydig cell tumors are a rare type of ovarian tumor that belong to the 'sex cord-stromal' family — tumors that grow from the ovary's hormone-producing support cells rather than its egg cells. They are named for the two cell types they contain (Sertoli and Leydig cells, normally found in the testicle), and many of them produce male hormones (androgens). This can cause signs such as irregular or absent periods, acne, a deeper voice, or increased body hair, which often prompt the diagnosis. They typically occur in teenagers and young women. Most are found early, confined to one ovary, and are cured by surgery alone. A notable subset is linked to inherited changes in a gene called DICER1, so genetic counseling is often recommended, especially in younger patients. Because behavior ranges from harmless to occasionally aggressive, the tumor's grade (how mature or 'well-differentiated' it looks) guides whether extra treatment is needed.

In one line: Sertoli-Leydig cell tumors are rare ovarian tumors that often make male hormones, usually affect young women, are mostly cured by fertility-sparing surgery, and only occasionally need chemotherapy or radiation.

The main types

Doctors group sertoli-leydig cell tumor of the ovary by where it starts and how it behaves:

TypeWhat it means, simply
Well-differentiatedLooks mature and orderly under the microscope; almost always benign and cured by removing the affected ovary.
Intermediate (moderately differentiated)An in-between appearance; usually behaves well but is watched more closely, and treatment may be added if other risk features are present.
Poorly differentiatedLooks immature and disorganized; the most likely to behave aggressively and the group most often considered for chemotherapy.
With heterologous elements / retiform patternContains extra tissue types (such as mucus glands or cartilage) or a net-like growth pattern; more often linked to DICER1 changes and to a somewhat higher risk of recurrence.

Staging, in plain terms

Sertoli-Leydig cell tumors use the same FIGO stages as other ovarian cancers to describe spread, but the tumor's grade (how differentiated it is) is just as important for predicting behavior. Most are stage I — confined to one ovary — when found.

Ovarian cancer FIGO staging (with grade emphasized)What it generally means
Stage IConfined to one (or rarely both) ovary. The great majority of cases, usually cured by surgery, especially when well-differentiated.
Stage IISpread to other pelvic structures. Less common; may prompt added chemotherapy depending on grade.
Stage IIISpread to the abdominal lining or lymph nodes. Uncommon; treated with surgery plus chemotherapy.
Stage IVSpread to distant organs. Rare for this tumor; managed with combined therapy at an expert center.
Plain-language takeaway: Staging tells your team how much disease there is and where — but your tumor's biology matters too. Two people described the same way can still have different plans, and that's a good thing.

The standard of care

Sertoli-Leydig Cell Tumor of the Ovary is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:

Fertility-sparing surgery

For early, one-sided tumors in young women, removing just the affected ovary and tube usually cures the cancer while preserving fertility and hormones.

More extensive surgery

For older patients who have completed childbearing, or for advanced tumors, more complete surgery with staging is performed.

Chemotherapy

Reserved mainly for poorly differentiated tumors, those with high-risk features, or advanced/recurrent disease — usually a platinum-based regimen similar to that used for ovarian germ-cell tumors.

Genetic counseling (DICER1)

Testing for inherited DICER1 changes is offered because it affects screening for the patient and family members for related tumors.

How radiation treatment works

Radiation damages the DNA inside cancer cells so they can no longer divide and survive, while normal cells repair themselves more effectively. For Sertoli-Leydig cell tumors, surgery is the main treatment and radiation has only a limited, selective role — for example, to control an isolated area of recurrence or to relieve symptoms. When it is used, it is delivered as short, painless daily sessions and leaves no radioactivity in your body, so you remain safe to be around family and children.

The main ways radiation is delivered for sertoli-leydig cell tumor of the ovary:

Radiation (selective)

Radiation is not a routine treatment for these tumors; it is used occasionally to control a specific site of recurrence or to relieve symptoms when surgery and chemotherapy are not options.

Stereotactic / focused radiation

When a single area of recurrent disease needs treatment, precisely targeted high-dose radiation can control it while sparing surrounding tissue.

Palliative radiation

Short courses of radiation can ease pain or other symptoms in the uncommon event of advanced, treatment-resistant disease.

Latest studies shaping care

Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:

DICER1 syndrome link clarified: Research has established that a meaningful share of Sertoli-Leydig cell tumors — particularly moderately/poorly differentiated and retiform types — carry DICER1 mutations that can be inherited, supporting routine genetic counseling.[1]

DICER1 tumor predisposition reviews (2021–2025)

Fertility-sparing surgery is safe for early tumors: Series confirm excellent outcomes with conservative, fertility-preserving surgery for stage I well-differentiated tumors, avoiding unnecessary chemotherapy.[2]

Gynecologic oncology outcome studies (2022–2024)

Chemotherapy targeted to high-risk disease: Platinum-based chemotherapy is reserved for poorly differentiated, advanced, or recurrent tumors, where it improves control, while low-risk tumors are spared its toxicity.[3]

Rare ovarian tumor consensus reviews (2023–2025)

Common questions

Will I still be able to have children? Usually yes. For young women with an early, one-sided tumor, surgeons can often remove only the affected ovary and fallopian tube, preserving the other ovary, the uterus, and fertility. Your team will tailor the plan to your situation.

Why did my voice deepen or my periods stop? Many of these tumors make male hormones, which can cause acne, increased body hair, a deeper voice, or changes in periods. These signs often lead to the diagnosis and usually improve after the tumor is removed.

Why am I being referred for genetic testing? Some Sertoli-Leydig cell tumors are caused by an inherited change in the DICER1 gene, which can predispose to a few other rare tumors. Testing helps guide monitoring for you and lets relatives know whether they should be checked too.

References

Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.

  1. DICER1 tumor predisposition reviews (2021–2025) (no indexed identifier — see your care team)
  2. Gynecologic oncology outcome studies (2022–2024) (no indexed identifier — see your care team)
  3. Rare ovarian tumor consensus reviews (2023–2025) (no indexed identifier — see your care team)
Medical disclaimer: This guide is general patient education, not medical advice, and reflects widely accepted standards as of 2026. Your situation is unique — always discuss your diagnosis and options with your own care team. CureRays clinicians are here to help you understand your choices.

Talk to a CureRays radiation oncologist Back to all guides